vs
徕博科（LH）与PILGRIMS PRIDE CORP（PPC）财务数据对比。点击上方公司名可切换其他公司
PILGRIMS PRIDE CORP的季度营收约是徕博科的1.3倍（$4.5B vs $3.5B），徕博科净利率更高（4.7% vs 1.9%，领先2.7%），徕博科同比增速更快（5.6% vs 3.3%），徕博科自由现金流更多（$490.3M vs $10.0M），过去两年徕博科的营收复合增速更高（5.2% vs 1.8%）
徕博科（Labcorp）是全球领先的生命科学与诊断检测企业，面向医疗机构、制药企业和个人患者提供全面的临床检验服务、药物研发支持及医疗检测解决方案，依托先进科研经验与创新技术输出准确可落地的健康洞察，助力临床决策、加快新药研发，提升全球患者健康水平。
Pilgrim's Pride是美国跨国食品企业，为美国及波多黎各最大的鸡肉生产商之一，同时是墨西哥第二大鸡肉生产商。公司2009年12月脱离破产状态，2011年将美国总部迁至科罗拉多州格里利，由JBS集团控股，2016年11月底以3.5亿美元收购Gold'n Plump。
LH vs PPC — 直观对比
营收规模更大
PPC
是对方的1.3倍
$3.5B
营收增速更快
LH
高出2.3%
3.3%
净利率更高
LH
高出2.7%
1.9%
自由现金流更多
LH
多$480.3M
$10.0M
两年增速更快
LH
近两年复合增速
1.8%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $3.5B | $4.5B |
| 净利润 | $164.7M | $88.0M |
| 毛利率 | 28.2% | 9.5% |
| 营业利润率 | 7.6% | 4.5% |
| 净利率 | 4.7% | 1.9% |
| 营收同比 | 5.6% | 3.3% |
| 净利润同比 | 14.9% | -62.7% |
| 每股收益（稀释后） | $1.98 | $0.37 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收LHPPC
| Q4 25 | $3.5B | $4.5B | ||
| Q3 25 | $3.6B | $4.8B | ||
| Q2 25 | $3.5B | $4.8B | ||
| Q1 25 | $3.3B | $4.5B | ||
| Q4 24 | $3.3B | $4.4B | ||
| Q3 24 | $3.3B | $4.6B | ||
| Q2 24 | $3.2B | $4.6B | ||
| Q1 24 | $3.2B | $4.4B |
净利润LHPPC
| Q4 25 | $164.7M | $88.0M | ||
| Q3 25 | $261.1M | $342.8M | ||
| Q2 25 | $237.9M | $355.5M | ||
| Q1 25 | $212.8M | $296.0M | ||
| Q4 24 | $143.4M | $235.9M | ||
| Q3 24 | $169.3M | $349.9M | ||
| Q2 24 | $205.3M | $326.3M | ||
| Q1 24 | $228.0M | $174.4M |
毛利率LHPPC
| Q4 25 | 28.2% | 9.5% | ||
| Q3 25 | 28.8% | 13.9% | ||
| Q2 25 | 29.7% | 15.0% | ||
| Q1 25 | 28.3% | 12.4% | ||
| Q4 24 | 26.9% | 12.7% | ||
| Q3 24 | 27.6% | 14.9% | ||
| Q2 24 | 28.8% | 15.2% | ||
| Q1 24 | 28.2% | 8.8% |
营业利润率LHPPC
| Q4 25 | 7.6% | 4.5% | ||
| Q3 25 | 11.1% | 10.4% | ||
| Q2 25 | 11.2% | 10.8% | ||
| Q1 25 | 9.7% | 9.1% | ||
| Q4 24 | 6.5% | 7.0% | ||
| Q3 24 | 7.7% | 11.1% | ||
| Q2 24 | 9.2% | 9.7% | ||
| Q1 24 | 10.1% | 5.7% |
净利率LHPPC
| Q4 25 | 4.7% | 1.9% | ||
| Q3 25 | 7.3% | 7.2% | ||
| Q2 25 | 6.7% | 7.5% | ||
| Q1 25 | 6.4% | 6.6% | ||
| Q4 24 | 4.3% | 5.4% | ||
| Q3 24 | 5.2% | 7.6% | ||
| Q2 24 | 6.4% | 7.2% | ||
| Q1 24 | 7.2% | 4.0% |
每股收益（稀释后）LHPPC
| Q4 25 | $1.98 | $0.37 | ||
| Q3 25 | $3.12 | $1.44 | ||
| Q2 25 | $2.84 | $1.49 | ||
| Q1 25 | $2.52 | $1.24 | ||
| Q4 24 | $1.72 | $1.00 | ||
| Q3 24 | $2.00 | $1.47 | ||
| Q2 24 | $2.43 | $1.37 | ||
| Q1 24 | $2.69 | $0.73 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $532.3M | $640.2M |
| 总债务越低越好 | — | $3.1B |
| 股东权益账面价值 | $8.6B | $3.7B |
| 总资产 | $18.4B | $10.3B |
| 负债/权益比越低杠杆越低 | — | 0.84× |
8季度趋势，按日历期对齐
现金及短期投资LHPPC
| Q4 25 | $532.3M | $640.2M | ||
| Q3 25 | $598.1M | $612.6M | ||
| Q2 25 | $647.3M | $849.0M | ||
| Q1 25 | $369.4M | $2.1B | ||
| Q4 24 | $1.5B | $2.0B | ||
| Q3 24 | $1.5B | $1.9B | ||
| Q2 24 | $265.1M | $1.3B | ||
| Q1 24 | $99.3M | $870.8M |
总债务LHPPC
| Q4 25 | — | $3.1B | ||
| Q3 25 | — | $3.1B | ||
| Q2 25 | — | $3.1B | ||
| Q1 25 | — | $3.2B | ||
| Q4 24 | — | $3.2B | ||
| Q3 24 | — | $3.2B | ||
| Q2 24 | — | $3.2B | ||
| Q1 24 | — | $3.3B |
股东权益LHPPC
| Q4 25 | $8.6B | $3.7B | ||
| Q3 25 | $8.7B | $3.5B | ||
| Q2 25 | $8.5B | $3.7B | ||
| Q1 25 | $8.3B | $3.1B | ||
| Q4 24 | $8.1B | $4.2B | ||
| Q3 24 | $8.2B | $4.2B | ||
| Q2 24 | $8.0B | $3.7B | ||
| Q1 24 | $8.0B | $3.5B |
总资产LHPPC
| Q4 25 | $18.4B | $10.3B | ||
| Q3 25 | $18.3B | $10.0B | ||
| Q2 25 | $18.1B | $10.1B | ||
| Q1 25 | $17.6B | $11.0B | ||
| Q4 24 | $18.4B | $10.7B | ||
| Q3 24 | $18.6B | $10.7B | ||
| Q2 24 | $16.7B | $10.1B | ||
| Q1 24 | $16.5B | $9.8B |
负债/权益比LHPPC
| Q4 25 | — | 0.84× | ||
| Q3 25 | — | 0.87× | ||
| Q2 25 | — | 0.83× | ||
| Q1 25 | — | 1.02× | ||
| Q4 24 | — | 0.76× | ||
| Q3 24 | — | 0.76× | ||
| Q2 24 | — | 0.85× | ||
| Q1 24 | — | 0.96× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $614.2M | $291.2M |
| 自由现金流经营现金流 - 资本支出 | $490.3M | $10.0M |
| 自由现金流率自由现金流/营收 | 13.9% | 0.2% |
| 资本支出强度资本支出/营收 | 3.5% | 6.2% |
| 现金转化率经营现金流/净利润 | 3.73× | 3.31× |
| 过去12个月自由现金流最近4个季度 | $1.2B | $653.1M |
8季度趋势，按日历期对齐
经营现金流LHPPC
| Q4 25 | $614.2M | $291.2M | ||
| Q3 25 | $387.2M | $458.3M | ||
| Q2 25 | $620.6M | $495.2M | ||
| Q1 25 | $18.5M | $126.9M | ||
| Q4 24 | $777.2M | $349.3M | ||
| Q3 24 | $277.3M | $651.1M | ||
| Q2 24 | $561.1M | $718.6M | ||
| Q1 24 | $-29.8M | $271.0M |
自由现金流LHPPC
| Q4 25 | $490.3M | $10.0M | ||
| Q3 25 | $280.5M | $275.9M | ||
| Q2 25 | $542.7M | $339.1M | ||
| Q1 25 | $-107.5M | $28.1M | ||
| Q4 24 | $665.1M | $176.6M | ||
| Q3 24 | $161.5M | $565.3M | ||
| Q2 24 | $432.9M | $617.7M | ||
| Q1 24 | $-163.6M | $171.9M |
自由现金流率LHPPC
| Q4 25 | 13.9% | 0.2% | ||
| Q3 25 | 7.9% | 5.8% | ||
| Q2 25 | 15.4% | 7.1% | ||
| Q1 25 | -3.2% | 0.6% | ||
| Q4 24 | 20.0% | 4.0% | ||
| Q3 24 | 4.9% | 12.3% | ||
| Q2 24 | 13.4% | 13.5% | ||
| Q1 24 | -5.2% | 3.9% |
资本支出强度LHPPC
| Q4 25 | 3.5% | 6.2% | ||
| Q3 25 | 3.0% | 3.8% | ||
| Q2 25 | 2.2% | 3.3% | ||
| Q1 25 | 3.8% | 2.2% | ||
| Q4 24 | 3.4% | 4.0% | ||
| Q3 24 | 3.5% | 1.9% | ||
| Q2 24 | 4.0% | 2.2% | ||
| Q1 24 | 4.2% | 2.3% |
现金转化率LHPPC
| Q4 25 | 3.73× | 3.31× | ||
| Q3 25 | 1.48× | 1.34× | ||
| Q2 25 | 2.61× | 1.39× | ||
| Q1 25 | 0.09× | 0.43× | ||
| Q4 24 | 5.42× | 1.48× | ||
| Q3 24 | 1.64× | 1.86× | ||
| Q2 24 | 2.73× | 2.20× | ||
| Q1 24 | -0.13× | 1.55× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
LH
| Diagnostics | $2.7B | 78% |
| Biopharma Laboratory Services | $793.0M | 23% |
PPC
| Retail | $1.5B | 33% |
| Europe Reportable Segment | $1.4B | 31% |
| Food Service | $889.2M | 20% |
| Prepared Product | $332.8M | 7% |
| Product Export | $122.7M | 3% |
| Other Sales Channel | $96.0M | 2% |
| Other Product And Service | $79.7M | 2% |
| Related Party | $21.7M | 0% |
| Seara Meats B.V. | $18.9M | 0% |
| Penasul UKLTD | $10.3M | 0% |
| JBSUSA Food Company | $5.4M | 0% |
